Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis

26 maj 2026 uppdaterad av: RenJi Hospital

Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis (The COMET Study)

A head-to-head comparison of two different types of percutaneous mechanical thrombectomy (PMT) - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - in patients with acute iliofemoral deep vein thrombosis (DVT) was conducted to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.

Studieöversikt

Detaljerad beskrivning

Acute deep venous thrombosis (DVT) is associated with development of post-thrombotic syndrome (PTS). Early removal of iliofemoral thrombosis by percutaneous mechanical thrombectomy (PMT) may reduce the incidence of PTS. There is currently a lack of research on which device is optimal for thrombus removal. The aim of this study is to conduct a multicenter, observational, prospective cohort study in patients with acute iliofemoral deep vein thrombosis (DVT), performing a head-to-head comparison of two different types of mechanical thrombectomy devices - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.

Studietyp

Observationell

Inskrivning (Beräknad)

180

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Shanghai, Kina
        • Rekrytering
        • Renji Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

180

Beskrivning

Inclusion Criteria:

  1. Aged between 18 and 85 years;
  2. Diagnosed with acute iliofemoral venous thrombosis, with thrombosis involving at least the iliac vein and common femoral vein;
  3. Time from symptom onset to endovascular treatment ≤ 14 days;
  4. Patients undergo endovascular treatment with percutaneous mechanical thrombectomy;
  5. Patients sign the informed consent form.

Exclusion Criteria:

  1. Presence of PTS in the limb to be treated in this procedure, or a history of symptomatic DVT in the same limb within the past 2 years;
  2. Concurrent symptomatic acute DVT involving the iliac vein and/or common femoral vein in the contralateral limb;
  3. Known allergy to heparin, low molecular weight heparin, contrast agents, etc.
  4. Concomitant severe pulmonary embolism with hemodynamic changes, such as hypoxia, hypotension, etc.
  5. Inability to tolerate endovascular treatment due to conditions such as acute systemic illness, severe dyspnea, etc.
  6. Concomitant severe renal insufficiency with creatinine clearance < 30 ml/min;
  7. Concomitant active bleeding, severe hepatic insufficiency, bleeding tendency, etc.
  8. Concomitant severe anemia (hemoglobin < 8.0 mg/dL) or platelet count < 80,000/mL;
  9. History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm;
  10. Pregnant women;
  11. Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency, etc.) with an expected life expectancy < 24 months
  12. Participation in any drug or medical device clinical trial that may interfere with this study within the past 1 month;
  13. Patients unwilling to participate in this trial.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
ClotTriever System group
Patients receive percutaneous mechanical thrombectomy by ClotTriever System
The procedure is performed via the ipsilateral popliteal vein access or the ipsilateral femoral vein access. After puncture under fluoroscopic or ultrasound guidance, a vascular sheath is inserted, systemic heparinization is administered, and a guidewire is advanced antegradely into the inferior vena cava with the assistance of a catheter to establish the access. Once the access is established, treatment is carried out using stent retriever devices. Available stent retriever devices include currently marketed options such as ClotTriever (INARI MEDICAL, USA). After thrombectomy, the thrombus removal efficacy is assessed by venography.
Aspiration thrombectomy group
Patients receive percutaneous mechanical thrombectomy by aspiration or rheolytic thrombectomy
The procedure is performed via the ipsilateral calf deep vein access, the ipsilateral popliteal vein access, or the ipsilateral femoral vein access. After puncture under fluoroscopic or ultrasound guidance, a vascular sheath is inserted, systemic heparinization is administered, and a guidewire is advanced antegradely into the inferior vena cava with the assistance of a catheter to establish the access. Once the access is established, treatment is carried out using mechanical aspiration thrombectomy devices. Available aspiration thrombectomy devices include currently marketed options such as the AngioJet thrombectomy catheter (Boston Scientific, USA) and the Acostream thrombectomy catheter (Acotec, China). After thrombectomy, the thrombus removal efficacy is assessed by venography.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of PTS
Tidsram: At 24 months
Assessed by the Villalta score
At 24 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of moderate-to-severe PTS
Tidsram: at 6, 12, and 24 months
Assessed by the Villalta score
at 6, 12, and 24 months
Clinical classification of Clinical-Etiology-Anatomy-Pathophysiology (CEAP)
Tidsram: at 6, 12, and 24 months
Based on clinical symptoms
at 6, 12, and 24 months
Patency rate of the ipsilateral iliofemoral vein
Tidsram: at 12 months and 24 months
Assessed by color Doppler ultrasound
at 12 months and 24 months
Incidence of PTS
Tidsram: Assessed by the Villalta score
at 6 and 12 months
Assessed by the Villalta score
Recurrence rate of symptomatic Deep Vein Thrombosis (DVT)
Tidsram: at 24 months
Assessed by symptoms combined with ultrasound examination in the ipsilateral limb
at 24 months
Rate of re-intervention
Tidsram: at 24 months
Assessed by documentation of clinical reintervention
at 24 months
Quality of life score
Tidsram: at 6, 12, and 24 months
Assessed by Venous Insufficiency Epidemiological and Economic Study Quality of Life questionnaire (VEINES-QOL)
at 6, 12, and 24 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of major bleeding
Tidsram: at 24 months
Defined by International Society on Thrombosis and Haemostasis (ISTH) criteria
at 24 months
Incidence of symptomatic Pulmonary Embolism (PE)
Tidsram: at 24 months
Assessed by symptoms combined with contrast-enhanced computed tomography examination
at 24 months
Incidence of symptomatic Venous Thromboembolism (VTE)
Tidsram: at 24 months
Assessed by symptoms combined with ultrasound and contrast-enhanced computed tomography examination
at 24 months
All-cause mortality
Tidsram: at 24 months
All-cause death
at 24 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 januari 2024

Primärt slutförande (Beräknad)

31 december 2027

Avslutad studie (Beräknad)

31 december 2028

Studieregistreringsdatum

Först inskickad

26 maj 2026

Först inskickad som uppfyllde QC-kriterierna

26 maj 2026

Första postat (Faktisk)

3 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

26 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera